BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8314652)

  • 1. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.
    Mihara M; Ohnishi A; Tomono Y; Hasegawa J; Shimamura Y; Yamazaki K; Morishita N
    Int J Clin Pharmacol Ther Toxicol; 1993 May; 31(5):223-9. PubMed ID: 8314652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
    Ohnishi A; Mihara M; Kamakura H; Tomono Y; Hasegawa J; Yamazaki K; Morishita N; Tanaka T
    J Clin Pharmacol; 1993 Nov; 33(11):1086-91. PubMed ID: 8300891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.
    Yasuda S; Ohnishi A; Ogawa T; Tomono Y; Hasegawa J; Nakai H; Shimamura Y; Morishita N
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):466-73. PubMed ID: 7820329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.
    Nagy CF; Kumar D; Cullen EI; Bolton WK; Marbury TC; Gutierrez MJ; Hutman HW; Pratt RD
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):18-24. PubMed ID: 15496219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Reyes JF; Preskorn SH; Khan A; Kumar D; Cullen EI; Perdomo CA; Pratt RD
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):50-7. PubMed ID: 15496223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.
    Periclou AP; Ventura D; Sherman T; Rao N; Abramowitz WT
    Ann Pharmacother; 2004 Sep; 38(9):1389-94. PubMed ID: 15266045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
    Terlinden R; Uragg H; Göhler K; Kneip C
    Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration.
    Tiseo PJ; Rogers SL; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):13-8. PubMed ID: 9839760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers.
    Ravic M; Warrington S; Boyce M; Dunn K; Johnston A
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):34-40. PubMed ID: 15496221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
    Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
    Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.